Drug
Ladarixin clinical trials
- studies test it
- 9
- open now
- 1
- in phase 3
- 0
- first study started
- 2012
Keep track of what changes. Save the ladarixin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2016 | 1 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 2
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ladarixin is read from its arms, and is right about nine times in ten.
Testing it · 9
- Ladarixin With Sotorasib in Advanced NSCLCRecruitingPhase 1NYU Langone HealthNCT05815173Written as Ladarixin
- A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell FunctionTerminatedPhase 2Dompé Farmaceutici S.p.ANCT04628481Written as Ladarixin
- A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.TerminatedPhase 2Dompé Farmaceutici S.p.ANCT04899271Written as Ladarixin
- Clinical Trial on Ladarixin Adjunctive Therapy to Improve Glycemic Control in Type 1 Diabetes.TerminatedPhase 2Dompé Farmaceutici S.p.ANCT05368402Written as Ladarixin
- A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 DiabetesCompletedPhase 2Dompé Farmaceutici S.p.ANCT02814838Written as Ladarixin
- Ladarixin With Sotorasib in Advanced NSCLC - Phase IIWithdrawnPhase 2NYU Langone HealthNCT05815186Written as Ladarixin
- A Single Dose Study About the Influence of Food on the Oral Bioavailability of Ladarixin Capsule in Healthy VolunteersCompletedPhase 1Dompé Farmaceutici S.p.ANCT04854642Written as Ladarixin
- Pilot Efficacy and Safety Study of Oral DF2156A in Patients With Active Bullous PemphigoidTerminatedPhase 2Dompé Farmaceutici S.p.ANCT01571895Written as DF2156A
- Ladarixin as Adjunctive Therapy to Improve Insulin Sensitivity and Glucometabolic Outcomes in Type 1 DiabetesWithdrawnPhase 2Dompé Farmaceutici S.p.ANCT05035368Written as Ladarixin
Codes
What other systems call ladarixin · ClinicalTrials.gg INT004937
- UNII (FDA) DEH7Q6472OLADARIXINConfirmed FDA, Wikidata
- Wikidata Q27276351ladarixinConfirmed FDA, Wikidata
- NCI Thesaurus C170087LadarixinOne source FDA
- DrugBank DB16212One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DEH7Q6472O | LADARIXIN | Confirmed FDA, Wikidata |
| Wikidata | Q27276351 | ladarixin | Confirmed FDA, Wikidata |
| NCI Thesaurus | C170087 | Ladarixin | One source FDA |
| DrugBank | DB16212 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.